Dataset from A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A

To assess efficacy and safety, including immunogenicity of BAX 855 administered as
prophylaxis and as on-demand therapy in adult and adolescent (12-65 years) previously treated
patients (PTPs) with severe hemophilia A To determine the pharmacokinetic (PK) parameters of
BAX 855.